Galimedix, Inc. | WebDisclosure

Basculer en Français

11280	Companies
250617	Keywords
179245	Articles
136434	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 03/05/2026 at 14:00, 7 months 30 days ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference
BRIEF

published on 12/04/2025 at 20:20, 11 months ago

Galimedix Therapeutics dévoile des résultats prometteurs de phase 1 pour le GAL-101

Résultats De La Phase 1 GAL-101 Traitement De La Maladie D'Alzheimer Barrière Hémato-encéphalique Planification De La Phase 2
BRIEF

published on 12/04/2025 at 20:20, 11 months ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 11 months ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025
BRIEF

published on 09/12/2025 at 13:25, 1 year 1 month ago

Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Clinical Trial Galimedix Therapeutics Alzheimer's Research Phase 1 Study GAL-101 Molecule
BRIEF

published on 09/12/2025 at 13:25, 1 year 1 month ago

Galimedix fait progresser la recherche sur la maladie d'Alzheimer grâce à la réussite de la phase 1

Essai Clinique Galimedix Therapeutics Étude De Phase 1 Recherche Sur La Maladie D'Alzheimer Molécule GAL-101
PRESS RELEASE

published on 09/12/2025 at 13:20, 1 year 1 month ago

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned

Alzheimer's Disease Phase 2 Trial GAL-101 Phase 1 Study Galimedix
BRIEF

published on 05/21/2025 at 14:05, 1 year 5 months ago

Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment

GAL-201 Neuroinflammation Alzheimer’s Treatment Amyloid-beta Synaptic Damage
BRIEF

published on 05/21/2025 at 14:05, 1 year 5 months ago

Le GAL-201 de Galimedix s'avère prometteur dans le traitement de la maladie d'Alzheimer

GAL-201 Neuroinflammation Traitement De La Maladie D'Alzheimer Bêta-amyloïde Dommages Synaptiques
PRESS RELEASE

published on 05/21/2025 at 14:00, 1 year 5 months ago

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

GAL-201 Galimedix Therapeutics Alzheimer’s Disease International Journal Of Molecular Sciences Neuroprotective Therapy

Accesswire

Published on 11/04/2026 at 23:10, 7 hours 57 minutes ago

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 8 hours 7 minutes ago

Avino Reports Q3 2026 Financial Results
Published on 11/04/2026 at 23:00, 8 hours 7 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 8 hours 52 minutes ago

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 9 hours 2 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 06:58, 9 minutes ago

Aareal Bank leverages its operational strength to set the course for its strategic future
Published on 11/05/2026 at 06:58, 9 minutes ago

AT&S reports record second-quarter results and fully confirms full-year guidance
Published on 11/05/2026 at 06:30, 37 minutes ago

HENSOLDT increases adjusted EBITDA by 33% and refines guidance for 2026 upwards
Published on 11/05/2026 at 06:30, 37 minutes ago

Formycon invites to conference call on 2026 nine-month results and announces participation in international investor conferences
Published on 11/05/2026 at 06:20, 47 minutes ago

Zhejiang Showcases Its Cultural and Tourism Appeal in Hamburg at "Come for the Stories" Event

Les Echos

Published on 11/04/2026 at 18:00, 13 hours 7 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 13 hours 7 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 13 hours 22 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 13 hours 22 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 13 hours 23 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE